News

Bristol Myers Squibb Reports Decreased Profit but Strong Revenue in Q4

1 Mins read

Bristol Myers Squibb, a leading biopharmaceutical company, experienced a decline in profit during the fourth quarter due to weaker margins. However, the company saw an unexpected increase in revenue, thanks to the strong performance of its drugs Eliquis and Opdivo.

Profit and Earnings

In the fourth quarter, Bristol Myers Squibb’s profit stood at $1.76 billion, or 87 cents per share. This is a decrease from the $2.02 billion, or 95 cents per share, reported in the same quarter of the previous year. When excluding one-time items, earnings were $1.70 per share, surpassing analyst predictions of $1.55 per share according to FactSet.

Revenue Growth

Despite expectations of falling revenue, Bristol Myers Squibb’s revenue rose to $11.48 billion in the fourth quarter, compared to $11.41 billion in the previous year’s quarter. Analysts polled by FactSet had anticipated a decrease to $11.19 billion. The growth was driven by increased sales of Eliquis, a blood thinner, and Opdivo, a cancer drug. These gains offset declines in revenue from their multiple-myeloma drug Revlimid due to competition from generic versions. The company’s new product portfolio also contributed to the positive revenue trend.

Gross Margins and Future Outlook

Bristol Myers Squibb faced a decline in gross margins due to their product mix and lower hedge settlement gains.

Looking ahead to 2024, the company aims to achieve low single-digit percentage growth in sales. They also expect adjusted earnings of $7.10 to $7.40 per share, surpassing current analyst estimates of $7.02 per share.

Related posts
News

$TRUMP and other meme coins won't be protected by SEC, Commissioner Hester Peirce says

3 Mins read
LAS VEGAS — Now that the SEC is out of the business of regulating meme coins, investors shouldn’t expect any guidance on…
News

Man charged in New York with 3-week kidnapping to try to steal Bitcoin

1 Mins read
NEW YORK (Reuters) -A grand jury has indicted a 37-year-old cryptocurrency investor accused of kidnapping a business partner inManhattan’s upscale Soho neighborhood…
News

Goldman Sachs Expert Predicts Significant Gold Price Surge by 2026

2 Mins read
Investors are advised to consider risk-reward balance and portfolio diversification.Trending NowBest Forex Trading Robots To Invest In 2022 Daan Struyven, co-head of…

Leave a Reply

Your email address will not be published. Required fields are marked *

15 − = 5